

WRITER'S DIRECT DIAL:
(713) 439-0108

April 10, 2007

Temp. Ref.: 3999.002587

CERTIFICATE OF ELECTRONIC FILING

This correspondence is being transmitted to the Commissioner for Patents, Alexandria, VA, via the Office electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4), on the date below:

April 10, 2007

Date

Sharon V. Hart

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: U.S. Application Serial No. 10/738,404; Entitled "Selective Anti-VEGF Antibody Prodrug Methods" (As Amended); by Thorpe and Brekken; U.T. Ref.: UTSD:1412-8 US; Peregrine Family: UTS06; Our Temp. Ref.: 3999.002587

Sir:

In the second Official Action dated December 15, 2006 ("the second Action"), the Office indicates that copies of Exhibits E, F, G, H and I, submitted with Applicants' first response, were not received and were thus not considered (second Action at page 8).

Applicants' records show submission of each of Exhibits A-K with the first response. From Applicants' current review, only Exhibit D appears to be located on PAIR. It can only be deduced that Exhibits A-C and Exhibits E-K became detached from the other materials upon receipt at the Office and were not scanned into the PAIR system. Thus, through no fault of the Applicants or the Examiner, the submitted exhibits did not reach the Examiner.

Presently enclosed to complete the record are electronic copies of Exhibits A-K, each of which were properly and timely submitted with Applicants' original first response.

Applicants will respond to the outstanding second Action within the extendable period for response. Applicants respectfully request consideration of the response to be filed in light of Exhibits A-K, particularly Exhibits E, F, G, H and I, each of which formed an integral part of Applicants' first response.

After Applicants' response to the second Action is filed, should Examiner Joyce have any questions or comments, a telephone call to the undersigned Applicants' representative is earnestly solicited.

April 10, 2007
Page 2

No fees are due in connection with the present submission. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, such fees should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/3999.002587.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.
Customer No. 000052101


Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

Encl.